Verici Dx PLC — LSE:VRCI is attracting investor attention amidinvestor focus on its transplant diagnostics tests and the pace of commercial adoption.
Aptamer Group PLC — LSE:APTA is attracting investor attention amidinvestor focus on its aptamer binder platform and its pharmaceutical partnerships.
Futura Medical PLC — LSE:FUM is attracting investor attention amidinvestor focus on the commercial rollout of its topical treatment and its distribution agreements.
Integrated Diagnostics Holdings PLC — LSE:IDHC is attracting investor attention amidinvestor focus on its Middle East and African diagnostics operations and Egyptian currency movements.
Nuformix PLC — LSE:NFX is attracting investor attention amidinvestor focus on its drug repurposing programmes and its cocrystal platform.
MedPal AI has gone from a pre-revenue AIM newcomer to an £8.6m revenue run-rate online pharmacy in under a year — but a wafer-thin cash balance and relentless share issuance keep the risks in plain view.
The York-based lateral-flow specialist has spent the past year rebuilding itself around contract development and manufacturing. After a trading update pointing to 31% revenue growth and a maiden move into second-half profitability, investors are weighing whether the momentum can carry into a bigger FY27.
Shares in Kromek Group (LSE:KMK) edged higher, adding close to 5% in a session that left the AIM-quoted radiation and bio-detection specialist back among the day's more actively watched small caps. For a company whose stock trades in single-digit pence and whose order flow …
Feedback plc, the AIM-listed maker of the Bleepa clinical-communications platform, jumped more than 11% in a single session, a reminder of how quickly sentiment can turn in a micro-cap whose fortunes are tied almost entirely to NHS spending decisions.
Shield Therapeutics' shares snapped higher as investors took a second look at half-year figures showing US prescriptions climbing and losses shrinking towards the company's long-promised profitability target. For aBusinessthat has leaned repeatedly on its largestShareholderfor cash, the question is whether commercial momentum can finally …